CMS Decision To Conduct Provenge NCA Could Be "Chilling To Future Innovation," BIO's Greenwood Says
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO CEO Jim Greenwood discusses his views on the Medicare national coverage analysis for Dendreon's prostate cancer immunotherapy Provenge with "The Pink Sheet" DAILY.
You may also be interested in...
Provenge Tops 500 Scripts Since Approval; Most Local Medicare Contractors Will Cover Product
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
Provenge Should Be "Very Familiar" To CMS Now, Dendreon Says About NCA
Dendreon has already provided the Centers for Medicare and Medicaid Services with extensive information on its new prostate cancer vaccine Provenge (sipuleucel-T), so a lengthy Medicare national coverage analysis is not needed, the firm maintained in July 27 comments to the agency
Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.